|
1
|
Sabattini E, Bacci F, Sagramoso C and
Pileri SA: WHO classification of tumours of haematopoietic and
lymphoid tissues in 2008: An overview. Pathologica. 102:83–87.
2010.PubMed/NCBI
|
|
2
|
Lenz G and Staudt LM: Aggressive
lymphomas. N Engl J Med. 362:1417–1429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Lu Y and Li X: miR-339-3p inhibits
proliferation and metastasis of colorectal cancer. Oncol Lett.
10:2842–2848. 2015.PubMed/NCBI
|
|
4
|
Vicente R, Noël D, Pers YM, Apparailly F
and Jorgensen C: Deregulation and therapeutic potential of
microRNAs in arthritic diseases. Nat Rev Rheumatol. 2015.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y,
Fan S and Liu Y: MicroRNA-187, down-regulated in clear cell renal
cell carcinoma and associated with lower survival, inhibits cell
growth and migration though targeting B7-H3. Biochem Biophys Res
Commun. 438:439–444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Casanova-Salas I, Rubio-Briones J,
Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A,
Rubio L, Ramírez-Backhaus M, Armiñán A, et al: Identification of
miR-187 and miR-182 as biomarkers of early diagnosis and prognosis
in patients with prostate cancer treated with radical
prostatectomy. J Urol. 192:252–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Locke JM, da Silva Xavier G, Dawe HR,
Rutter GA and Harries LW: Increased expression of miR-187 in human
islets from individuals with type 2 diabetes is associated with
reduced glucose-stimulated insulin secretion. Diabetologia.
57:122–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang CC, Ye BH, Chaganti RS and
Dalla-Favera R: BCL-6, a POZ/zinc-finger protein, is a
sequence-specific transcriptional repressor. Proc Natl Acad Sci
USA. 93:6947–6952. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jardin F, Ruminy P, Bastard C and Tilly H:
The BCL6 proto-oncogene: A leading role during germinal center
development and lymphomagenesis. Pathol Biol (Paris). 55:73–83.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duan S, Cermak L, Pagan JK, Rossi M,
Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R and Pagano
M: FBXO11 targets BCL6 for degradation and is inactivated in
diffuse large B-cell lymphomas. Nature. 481:90–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pasqualucci L, Bereshchenko O, Niu H,
Klein U, Basso K, Guglielmino R, Cattoretti G and Dalla-Favera R:
Molecular pathogenesis of non-Hodgkin's lymphoma: The role of
Bcl-6. Leuk Lymphoma. 44(Suppl 3): S5–S12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ye BH: BCL-6 in the pathogenesis of
non-Hodgkin's lymphoma. Cancer Invest. 18:356–365. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anstaett OL, Brownlie J, Collins ME and
Thomas CJ: Validation of endogenous reference genes for RT-qPCR
normalisation in bovine lymphoid cells (BL-3) infected with Bovine
Viral Diarrhoea Virus (BVDV). Vet Immunol Immunopathol.
137:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang N, Chen W, Zhang JW, Li Y, Zeng XC,
Zhang T, Fu BS, Yi HM and Zhang Q: Aberrantly regulated dysadherin
and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances
tumorigenesis and DNA targeting drug resistance of liver cancer
stem cells. Mol Med Rep. 12:7239–7246. 2015.PubMed/NCBI
|
|
15
|
Camicia R, Winkler HC and Hassa PO: Novel
drug targets for personalized precision medicine in
relapsed/refractory diffuse large B-cell lymphoma: A comprehensive
review. Mol Cancer. 14:2072015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soriano A, Jubierre L, Almazán-Moga A,
Molist C, Roma J, de Toledo JS, Gallego S and Segura MF: MicroRNAs
as pharmacological targets in cancer. Pharmacol Res. 75:3–14. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mulrane L, Madden SF, Brennan DJ, Gremel
G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG,
et al: miR-187 is an independent prognostic factor in breast cancer
and confers increased invasive potential in vitro. Clin
Cancer Res. 18:6702–6713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chao A, Lin CY, Lee YS, Tsai CL, Wei PC,
Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of
ovarian cancer progression by microRNA-187 through targeting
Disabled homolog-2. Oncogene. 31:764–775. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Q, Liu X, Yan H, He YH, Ye S, Cheng XW,
Zhu GL, Wu WY, Wang XN, Kong XJ, et al: B-cell lymphoma 6 protein
stimulates oncogenicity of human breast cancer cells. BMC Cancer.
14:4182014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bajalica-Lagercrantz S, Piehl F, Farnebo
F, Larsson C and Lagercrantz J: Expression of the BCL6 gene in the
pre- and postnatal mouse. Biochem Biophys Res Commun. 247:357–360.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bos R, van Diest PJ, van der Groep P,
Greijer AE, Hermsen MA, Heijnen I, Meijer GA, Baak JP, Pinedo HM,
van der Wall E and Shvarts A: Protein expression of B-cell lymphoma
gene 6 (BCL-6) in invasive breast cancer is associated with cyclin
D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene.
22:8948–8951. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Polo JM, Dell'Oso T, Ranuncolo SM,
Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD and Melnick
A: Specific peptide interference reveals BCL6 transcriptional and
oncogenic mechanisms in B-cell lymphoma cells. Nat Med.
10:1329–1335. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polo JM, Juszczynski P, Monti S,
Cerchietti L, Ye K, Greally JM, Shipp M and Melnick A:
Transcriptional signature with differential expression of BCL6
target genes accurately identifies BCL6-dependent diffuse large B
cell lymphomas. Proc Natl Acad Sci USA. 104:3207–3212. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cerchietti LC, Yang SN, Shaknovich R,
Hatzi K, Polo JM, Chadburn A, Dowdy SF and Melnick A: A
peptomimetic inhibitor of BCL6 with potent antilymphoma effects in
vitro and in vivo. Blood. 113:3397–3405. 2009. View Article : Google Scholar : PubMed/NCBI
|
